Midstage Vitae drug flops in PhII, leaving Allergan’s $640M buyout in question

Allergan ($AGN) took an R&D hit this quarter as it emerged from analysts that a Phase II test of dermatology med VTP-38543, acquired as part of a $640 million buyout deal of Vitae in September, has failed.

The med, a topical LXRβ (liver X receptor beta) selective agonist aimed at treating atopic dermatitis, “failed to show a positive signal in proof of concept,” according to analysts from Leerink and Evercore ISI.

The drug was one of the two leading meds in Vitae’s pipeline, the other being the midstage psoriasis med VTP-43742, and leads to questions over its purchase--coming as it also noted in its Q3 that it was to buy back $10 billion in an accelerated share repurchase program.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

Leerink put the med’s failure in the “Things we didn’t like about this quarter” for the acquisitive Allergan.

The deal to buy Vitae, one of many in recent months, was worth $21 a share and became a major premium on the $8 a share it was trading on the day before the acquisition was announced, when it had a market cap of $238 million.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.